Feed / CGC

Canopy Growth Corporation

CGC

Healthcare · 0.92 -4.1% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Canopy Growth Corporation's current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 20 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.

Company-4.1% todayVolume comparison unavailable
Market group0 of 20 activeBiotechnology and Diagnostics · unavailable
Disclosed network0 of 7 confirmingNo filing-linked name is confirming now
What would change this read
  • CGC's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if CGC's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Drug Manufacturers - Specialty & Generic

No new filing conclusion is available. 0 of 20 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 7 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • CGC's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations319
Usable filing statements246
Verified relationships8
Evidence supporting the case
  • Latest annual revenue changed +5.8% year over year.
  • Net margin changed +96.8 percentage points in the latest annual period.
Evidence challenging the case
  • Operating margin changed -13.3 percentage points in the latest annual period.
  • Product pipeline and R&D has repeated adverse evidence across 5 filings.
Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 10, 2026

0.92
6m-17.5%12m-38.8%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2022-03-31$475.7M-21.7%$-7.92
2023-03-31$333.3M-29.9%$-70.69+18.5%
2024-03-31$297.1M-10.8%$-9.27
2025-03-31$269.0M-9.5%$-4.73+43.8%
2026-03-31$284.6M+5.8%$-0.88

What management says matters

Persistent and emerging business drivers

Product pipeline and R&Dmixed · 5 filings
The year-over-year decrease in the gross margin percentage was primarily attributable to lower sales relating to international markets cannabis, higher inventory provisions, costs related to new product launches and a shift in both product and geographical mi…
10-K · Jun 15, 2026
Legal and regulatory exposuremixed · 4 filings
For the year ended March 31, 2026, a new litigation provision was recorded as a result of legal proceeding developments during the period.
10-K · Jun 15, 2026
Credit and interest ratesnegative · 3 filings
24, the Credit Facility matured on December 18, 2026, and after December 26, 2023, interest on amounts outstanding under the Credit Facility was calculated at either the applicable prime rate plus 7.50 % per annum, subject to a prime rate floor of 2.00 %, or…
10-K · Jun 15, 2026
Demand and volumenegative · 2 filings
The year-over-year increase is primarily attributable to an increase in the average size of medical orders placed by our customers due largely to an increase in the percentage of insured customers, and a larger assortment of cannabis product choices offered t…
10-K · Jun 15, 2026

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

0.92-4.1% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for CGC. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for CGC. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind CGC

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TDThe Toronto-Dominion BankcustomerJun 15, 2026

Our Apollo clinic has been named Best Medical Cannabis Clinic in the 2025 Toronto Star’s Readers’ Choice Awards, a public vote that reflects the trust patients place in Apollo’s care.

TSNDFFiling-linked nameinvesteeJun 15, 2026

TerrAscend – the Canopy USA LPs hold an aggregate of 64,564,487 common shares (the “TerrAscend Common Shares”) in the capital of TerrAscend Corp.

BTIBritish American Tobacco p.l.c.partnerMay 30, 2025

Adult-Use Our cannabis cultivation operations are focused in two facilities, our hybrid greenhouse facility in Kincardine, Ontario and the DOJA greenhouse facility in Kelowna, British Columbia.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

CGC is currently a Follower in the organic co-movement group Biotechnology and Diagnostics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for CGC; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.